Acta Obstetricia et Gynecologica Scandinavica | 2021
Use of sildenafil and other phosphodiesterase type 5 inhibitors among pregnant women in Scandinavia
Abstract
For phosphodiesterase type 5 (PDE5) inhibitors, such as sildenafil, the only approved indication in women is for pulmonary arterial hypertension. These drugs are increasingly being proposed and tested for treatment of female infertility and complications in pregnancy. However, the extent of use of PDE5 inhibitors in the general pregnant population over the last decades is unknown. Therefore, we conducted a descriptive cohort study using data from the population health registers in the Scandinavian countries.